-

MedsEngine Helps Medical Practices Unlock $30,000 Per Provider in Additional Annual Revenue

DAYTON, Ohio--(BUSINESS WIRE)--MedsEngine, a leader in chronic disease management software, announced today that medical practices using its Cholesterol and Type 2 Diabetes modules could generate up to $30,000 in additional annual revenue. This estimate is based on a typical patient panel of 2,000 and leverages national averages and published financial data related to these chronic conditions.

MedsEngine Provides Revenue Opportunity

Share

“Using MedsEngine is a win-win for providers and patients,” said Dr. Doug Romer, Chief Medical Officer of MedsEngine. “Providers are reimbursed for following clinical guidelines, and patients benefit from being on the right medications. Practices also see improved efficiency through better use of APPs, which can help streamline workflow and expand patient capacity.”

Dr. Romer emphasized the system’s practical origins. “MedsEngine was developed out of necessity—built while managing 25–30 patients a day. If it didn’t save time and deliver results, it wouldn’t have survived in a busy clinical environment.”

MedsEngine empowers clinicians to efficiently manage chronic conditions across their entire patient population. It delivers evidence-based, guideline-directed medication recommendations in seconds, helping providers have more meaningful conversations with patients at the point of care.

Clinicians using MedsEngine report enhanced communication, with visual tools that help explain conditions and treatments clearly. One user shared, “Medication adherence has improved, and our control rates are better than ever. The automated calculation of personalized A1c and LDL-C targets during visits is incredibly helpful.”

Ray Kaiser, CTO of MedsEngine, highlighted the platform’s ease of use and rapid deployment: “MedsEngine integrates with EHRs using FHIR technology, is SOC 2 Type II compliant, and cloud-based. Most practices are up and running within 2–3 weeks, typically requiring just 10–20 hours to integrate (no installation) with existing EHR systems.”

Health insurers also see significant savings. A validated study from Ochsner found that proper treatment of Type 2 Diabetes could reduce costs by $1,956 per patient annually. Several studies have shown that controlling hypertension can save from $1,800 - $2,500 per patient annually.

Contacts

For more information, please contact us at hello@medsengine.com

MedsEngine


Release Versions

Contacts

For more information, please contact us at hello@medsengine.com

More News From MedsEngine

MedsEngine Achieves High Blood Pressure Control In Less Than Two Office Visits

DAYTON, Ohio--(BUSINESS WIRE)--MedsEngine LLC, a provider of chronic disease management software, presented its findings on blood pressure control to the European Society of Hypertension in Milan, Italy, May 23-26, 2025. The findings showed that users of the MedsEngine Hypertension module were able to achieve high BP control rates, to a goal of <140/90, in less than two office visits. These results build on earlier presentations at the European Society of Cardiology Congress in 2023 and 2024...

MedsEngine Achieves SOC 2 Type II Certification: Reinforcing Our Commitment to Data Security

DAYTON, Ohio--(BUSINESS WIRE)--MedsEngine, a provider of chronic disease management software, is proud to announce that it has successfully attained SOC 2 Type II certification. This certification, awarded by the American Institute of Certified Public Accountants (AICPA), is a rigorous audit that evaluates a company's controls relevant to security, availability, processing integrity, confidentiality, and privacy. Dr. Doug Romer, CMO, stated, “this milestone underscores MedsEngine’s continued co...

MedsEngine Selected as Finalist in Payor Category of the Emerge Innovation Contest at HIMSS25

DAYTON, Ohio--(BUSINESS WIRE)--MedsEngine, a clinical decision support software designed to optimize treatment for hypertension, cholesterol, type 2 diabetes, and heart failure, is proud to announce they were selected as a finalist in the payor category of the Emerge Innovation Experience Contest at HIMSS25. Dr. Doug Romer, MedsEngine CMO, stated, “given the level of competition, having MedsEngine recognized among innovative solutions that are transforming healthcare delivery is truly an honor...
Back to Newsroom